News › Clinical Practice, Industry News, Patient Care

FDA approves first treatment for advanced form of the second most common skin cancer

September 28, 2018

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.
Libtayo works by targeting the cellular pathway known as PD-1 (protein found on the body’s immune cells and some cancer cells). By blocking this pathway, the drug may help the body’s immune system fight the cancer cells.
Read more at FDA.gov >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics Refreshes Allergan Partner Privileges to Better Support Today’s Modern Aesthetics Practices
    • Galderma Receives EU Approval for Restylane Shaype: Bone-Mimicking Hyaluronic Acid Injectable for Chin
    • Merz Aesthetics’ Ultherapy PRIME Gains FDA Clearance for Knee Skin Laxity
    • USA Payments Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Accepts Supplemental Biologics License Application for Botox Cosmetic for Masseter Muscle Prominence
Advertisement